Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00509548 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD
A Phase 2 study, sponsored by TargeGen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00509548 is a Phase 2 study that was terminated before completion, run by TargeGen. The registered enrollment target is 7 participants.
The verdict
NCT00509548, a Phase 2 study, was terminated before completion, sponsored by TargeGen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision or cause vision loss. TG100801 is a topical (eye drop) therapy that has been shown to inhibit ocular angiogenesis, vascular leak, and inflammation in laboratory studies. The primary purpose of this pilot study is to evaluate the ability of topical administration of TG100801 to reduce the amount of fluid in the retina in patients with AMD following 30 days of treatment. An additional objective is to evaluate the safety of TG100801 in patients with AMD.
Interventions
- DRUG TG100801
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2007-07 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00509548
The ClinicalTrials.gov registry entry for NCT00509548 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TargeGen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TG100801 is the first listed.
NCT00509548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00509548 about?
NCT00509548 is a clinical study titled "Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD". Wet age-related macular degeneration (AMD) is caused by the formation and growth of abnormal blood vessels (angiogenesis) in the retina. The new blood vessels have fragile walls and can leak fluid into the retina. The build-up of fluid (edema) under the macula can distort vision or cause vision loss...
What is the current status of trial NCT00509548?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2007-07. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00509548?
The interventions under investigation include: TG100801 (DRUG).
Who is sponsoring clinical trial NCT00509548?
This trial is sponsored by TargeGen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.